Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake: A Pilot Study to Determine if a Polygenic Risk Score Influences the Decision to Accept Breast Cancer Preventive Medications (Tamoxifen, Raloxifene, or Exemestane) Amongst Non-BRCA Women at Risk

NCT02517593 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02517593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02517593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake: A Pilot Study to Determine if a Polygenic Risk Score Influences the Decision to Accept Breast Cancer Preventive Medications (Tamoxifen, Raloxifene, or Exemestane) Amongst Non-BRCA Women at Risk
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2016
Completion date
December 1, 2019
Enrollment
151 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer